Investor Presentaiton

Significant untapped potential in the Therapy Selection market INVESTOR 20 DAY 23 700K Total Patients $10B Total Addressable Market GUARDANT™ Sources: Therapy selection TAM is Stage IV patients., Data from internal modeling that sources information from US Cancer Statistics; SEER, Cancer MPact®, NODA data, Treatment Architecture, peer-reviewed literature, and Guardant Health data on file. 76

View entire presentation